Duloxetine Delayed-Release Capsules, 30mg recall — Breckenridge Pharmaceutical, Inc. (Class II)
Breckenridge Pharmaceutical, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Duloxetine Delayed-Release Capsules, 30mg — a Class II recall, initiated 2026-06-04 and posted to the FDA enforcement report on 2026-06-17, under recall number D-0582-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit”. From the product description, the form is delayed-release capsules, the strength given is 30mg, the package is described as 1000 Capsule and it is marked Rx only. 1 National Drug Code number is printed in the record: 51991-747-10. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NJ, United States. The FDA files it under event ID 99108 together with 1 other recall number, all listed and linked below. Within that event this is the strength 30mg, package 1000 Capsule and ndc 51991-747-10 configuration; the sibling records differ on strength, package and ndc and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0582-2026 |
|---|---|
| FDA event ID | 99108 (2 recall numbers) |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Recall initiated | 2026-06-04 |
| Reported by FDA | 2026-06-17 |
| Report lag | 13 days from initiation to report |
| Distribution | Nationwide within the United States — Nationwide (US) |
| Firm location on record | NJ, United States |
| Product description (source) | Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10 |
Reason reported by FDA
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
11 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.
| Product named | Duloxetine Delayed-Release Capsules |
|---|---|
| Form | Delayed-Release Capsules |
| Strength | 30mg |
| Package | 1000 Capsule |
| NDC | 51991-747-10 |
| Marketing category | Rx only |
| Distributed by | Breckenridge Pharmaceuticals, Inc. |
Which configuration this record is
2 recall numbers share event 99108. They differ on strength, package and ndc and agree on everything else the source states, so those are the values to check a package against.
| Attribute | This record (D-0582-2026) | D-0583-2026 |
|---|---|---|
| Strength | 30mg | 60mg |
| Package | 1000 Capsule | 90 Capsules (NDC 51991-748-90) · 1000 Capsules (51991-748-10) |
| NDC | 51991-747-10 | 51991-748-90 |
Shared across all 2 records under this event: form Delayed-Release Capsules; product named Duloxetine Delayed-Release Capsules; fda tier Class II; recalling firm Breckenridge Pharmaceutical, Inc.; the same reason text; initiated 2026-06-04; reported 2026-06-17.
Event context: 2 recall numbers under event 99108
One enforcement action, 2 recall numbers: the FDA filed 1 further configuration of this action under event 99108. Each keeps its own recall number and dates.
| Recall record | Recall number | FDA tier | Strength / form | NDC | Reported |
|---|---|---|---|---|---|
| Duloxetine Delayed-Release Capsules, 60mg | D-0583-2026 | Class II | 60mg · Delayed-Release Capsules | 51991-748-90 | 2026-06-17 |
Other indexed recalls from Breckenridge Pharmaceutical, Inc.
3 indexed records name Breckenridge Pharmaceutical, Inc. as the recalling firm, across 2 FDA events, reported 2026-05-13 to 2026-06-17. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Duloxetine Delayed-Release Capsules USP, 60mg | D-0522-2026 | Class II | 60mg · Delayed-Release Capsules | 2026-05-13 |
Other indexed recalls of duloxetine
6 indexed records name duloxetine as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | 30 mg · Delayed-Release Capsules | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | 60 mg · Delayed-Release Capsules | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | 20 mg · Delayed-Release Capsules | 2026-05-13 |
Reported in the same month (2026-06)
74 enforcement reports carry a report date in 2026-06; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Zep, 70% | D-0586-2026 | Zep Inc | Class II | 2026-06-17 |
| GSMS Incorporated, 1,000 MG | D-0587-2026 | Golden State Medical Supply Inc. | Class II | 2026-06-17 |
| Minocycline Hydrochloride Extended-Release Tablets, 115 mg | D-0597-2026 | Ascend Laboratories, LLC | Class II | 2026-06-17 |
| Budesonide Inhalation Suspension, 1mg/2mL | D-0607-2026 | Sun Pharmaceutical Industries Inc | Class II | 2026-06-17 |
| Lidocaine HCl Injection USP | D-0554-2026 | Spectra Medical Devices, LLC | Class II | 2026-06-10 |
| Duloxetine DR Capsules, 30 mg | D-0555-2026 | Asclemed Usa Inc. | Class II | 2026-06-10 |
| Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg | D-0556-2026 | Ascend Laboratories, LLC | Class II | 2026-06-10 |
| KIRKLAND Signature, 1000 mg | D-0557-2026 | Guardian Drug Co. Inc. | Class II | 2026-06-10 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 3 nearest to 2026-06-17 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| HALEON CALCIUM CARBONATE TUMS ANTACID, 1000 mg | D-0558-2026 | Guardian Drug Co. Inc. | 1000 mg · Tablets | 2026-06-10 |
| HALEON CALCIUM CARBONATE TUMS ANTACID, 750 mg | D-0559-2026 | Guardian Drug Co. Inc. | 750 mg · Tablets | 2026-06-10 |
| Good Neighbor Pharmacy, 750 mg | D-0560-2026 | Guardian Drug Co. Inc. | 750 mg | 2026-06-10 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 99108 returns all 2 of these recall numbers; a search on D-0582-2026 returns only this configuration. Match a package against 51991-747-10 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Breckenridge Pharmaceutical, Inc. (3 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0582-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0582-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-06-17
- Ingested
- 2026-08-22
- Record hash
880251d15a48bfe5
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.